reports
- ING Helpdesk
Benelux Morning Notes
Colruyt: FY24/25F set to be in line with recently revised guidance. Exor: In search of a €2bn deal. Flow Traders: Sell In May And Go Away. Kinepolis: Peer Cineplex May 2025 box office revenue up 63% YoY, at 81% of 2019 level. Staffing: Dutch Period 5 - May vols up, strong pricing, working days/comps might distort. Staffing: French staffing - strong April data, May outlook also better
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Bo...
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company’s Annual General Meeting. Mark Pruzanski, C...
Inventiva Annonce la Nomination de Renée Aguiar-Lucander à son Conseil...
Inventiva Annonce la Nomination de Renée Aguiar-Lucander à son Conseil d’Administration Daix (France), New York City (New York, États-Unis), le 10 juin 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui la nomination de Renée Aguiar-Lucander à son Conseil d’administration. Cette nomination a été approuvée par les actionnaires lors de récente Assemblée Générale An...
- ING Helpdesk
- Guy Sips
Floridienne Strong gains for Biotrop offset by greenhouse market press...
Floridienne reported, without giving exact numbers, 1Q25 sales growth driven by the exceptional momentum of Biotrop. recording a significant increase in both revenue and profitability thanks to the success of its biological solutions for open-field crops in the Brazilian market. At the same time BioFirst (previously known as BioBest) saw increased competition in North America in the greenhouse cultivation segment, impacting the profitability of its legacy activities. We maintain our € 835 TP and...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Hilde Van Boxstael
- Kristof Samoy
- Wim Lewi
CMB.TECH NV AND GOLDEN OCEAN GROUP LIMITED ANNOUNCE AGREEMENT AND PLAN...
CMB.TECH NV AND GOLDEN OCEAN GROUP LIMITED ANNOUNCE AGREEMENT AND PLAN OF MERGER Antwerp, May 28, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV AND GOLDEN OCEAN GROUP LIMITED ANNOUNCE AGREEMENT AND PLAN OF MERGER CMB.TECH NV (NYSE: CMBT & Euronext Brussels: CMBT) (“CMB.TECH”) and Golden Ocean Group Limited (NASDAQ: GOGL & Euronext Oslo Børs: GOGL) (“Golden Ocean”) are pleased to announce that they have signed an agreement and plan of merger (the “Merger Agreement”) for a stock-for-stock merger, as contemplated by the term sheet previously announced on 22 April 2025. The transaction is structur...
Inventiva to Participate in the Upcoming Jefferies Global Healthcare C...
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s Management will participate in two upcoming investor conferences in June 2025. Frédéric Cren, CEO and cofounder of Inventiva, will p...
Inventiva Participera à la « Jefferies Global Healthcare Conference » ...
Inventiva Participera à la « Jefferies Global Healthcare Conference » et à la « UBS Spring Biotech Conference » Daix (France), New York City (New York, Etats-Unis), le 27 mai 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce aujourd’hui que son équipe de direction participera à deux conférences investisseurs au cours du mois de juin 2025. Frédéric Cren, directeur général et c...
- ING Helpdesk
- Bruno Cavalier
- Wim Gille
BEKB BEKAERT SA
DGE DIAGEO PLC
APAML APERAM SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
BFIT BASIC-FIT NV
RI PERNOD RICARD SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
RCO REMY COINTREAU SA
SBMO SBM OFFSHORE NV
UNIQA INSURANCE GROUP AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
LPE LAURENT-PERRIER SA
KER KERING SA
RAND RANDSTAD NV
SOLB SOLVAY SA
01913 PRADA S.P.A.
ARCAD ARCADIS NV
SLIGR SLIGRO FOOD GROUP N.V.
MONC MONCLER SPA
LIGHT SIGNIFY NV
TWEKA TKH GROUP N.V. CERT
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
CSM CORBION NV
INX IMCD N.V.
TRP TERAPLAST
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ASML ASML HOLDING NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ALFEN ALFEN NV
TOM2 TOMTOM NV
DSC1 DUTCH STAR C SHAR
CPR DAVIDE CAMPARI-MILANO N.V.
FAST FASTNED
INPST INPOST S.A.
- Bruno Cavalier
- Wim Gille
BEKB BEKAERT SA
DGE DIAGEO PLC
APAML APERAM SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
BFIT BASIC-FIT NV
RI PERNOD RICARD SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
RCO REMY COINTREAU SA
SBMO SBM OFFSHORE NV
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
RAND RANDSTAD NV
SOLB SOLVAY SA
01913 PRADA S.P.A.
ARCAD ARCADIS NV
SLIGR SLIGRO FOOD GROUP N.V.
MONC MONCLER SPA
LIGHT SIGNIFY NV
TWEKA TKH GROUP N.V. CERT
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
CSM CORBION NV
INX IMCD N.V.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ASML ASML HOLDING NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ALFEN ALFEN NV
TOM2 TOMTOM NV
DSC1 DUTCH STAR C SHAR
CPR DAVIDE CAMPARI-MILANO N.V.
FAST FASTNED
INPST INPOST S.A.
- Bruno Cavalier
- Wim Gille
BEKB BEKAERT SA
DGE DIAGEO PLC
APAML APERAM SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
BFIT BASIC-FIT NV
RI PERNOD RICARD SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
RCO REMY COINTREAU SA
SBMO SBM OFFSHORE NV
UNIQA INSURANCE GROUP AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
LPE LAURENT-PERRIER SA
KER KERING SA
RAND RANDSTAD NV
SOLB SOLVAY SA
01913 PRADA S.P.A.
ARCAD ARCADIS NV
SLIGR SLIGRO FOOD GROUP N.V.
MONC MONCLER SPA
LIGHT SIGNIFY NV
TWEKA TKH GROUP N.V. CERT
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
CSM CORBION NV
INX IMCD N.V.
TRP TERAPLAST
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ASML ASML HOLDING NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ALFEN ALFEN NV
TOM2 TOMTOM NV
DSC1 DUTCH STAR C SHAR
CPR DAVIDE CAMPARI-MILANO N.V.
FAST FASTNED
INPST INPOST S.A.
- Bruno Cavalier
- Wim Gille
BEKB BEKAERT SA
DGE DIAGEO PLC
APAML APERAM SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
BFIT BASIC-FIT NV
RI PERNOD RICARD SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
RCO REMY COINTREAU SA
SBMO SBM OFFSHORE NV
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
RAND RANDSTAD NV
SOLB SOLVAY SA
01913 PRADA S.P.A.
ARCAD ARCADIS NV
SLIGR SLIGRO FOOD GROUP N.V.
MONC MONCLER SPA
LIGHT SIGNIFY NV
TWEKA TKH GROUP N.V. CERT
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
CSM CORBION NV
INX IMCD N.V.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ASML ASML HOLDING NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ALFEN ALFEN NV
TOM2 TOMTOM NV
DSC1 DUTCH STAR C SHAR
CPR DAVIDE CAMPARI-MILANO N.V.
FAST FASTNED
INPST INPOST S.A.
- Wim Gille
BEKB BEKAERT SA
APAML APERAM SA
BFIT BASIC-FIT NV
SBMO SBM OFFSHORE NV
RAND RANDSTAD NV
SOLB SOLVAY SA
ARCAD ARCADIS NV
SLIGR SLIGRO FOOD GROUP N.V.
LIGHT SIGNIFY NV
TWEKA TKH GROUP N.V. CERT
CSM CORBION NV
INX IMCD N.V.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ASML ASML HOLDING NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ALFEN ALFEN NV
TOM2 TOMTOM NV
DSC1 DUTCH STAR C SHAR
FAST FASTNED
INPST INPOST S.A.
- Jacob Mekhael
Inventiva Uneventful 1Q25 results, runway and pipeline timelines reite...
Inventiva reported uneventful 1Q25 results, and confirmed its cash runway guidance, which is until the end of 3Q26. Timeline for the topline readout from the ongoing phase 3 trial of lanifibranor in MASH was also reiterated, with results expected in 2H26. With the funding overhang lifted, a fully recruited phase 3 trial in MASH, as well as competitive phase 2 data, we continue to see Inventiva as significantly undervalued and reiterate our € 7 TP and Buy rating.
Inventiva reports 2025 First Quarter Financial Information¹
Inventiva reports 2025 First Quarter Financial Information¹ Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported financial information for the first quarter of 2025, including its cash, cash equivalents and revenues. Key Financial Results Cash, cash equivalents and deposits As of March 3...
Inventiva publie ses informations financières¹ du 1er trimestre 2025
Inventiva publie ses informations financières¹ du 1er trimestre 2025 Trésorerie et équivalents de trésorerie à 67,9 millions d’euros Daix (France), New York City (New York, Etats-Unis), le 23 mai 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), publie aujourd’hui ses informations financières du 1er trimestre 2025 dont sa trésorerie, ses équivalents de trésorerie et son chiffre d’af...
Results of the Votes of the Combined Shareholders’ General Meeting of ...
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025 Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Thursday May 22, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (Fr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.